Flow cytometry analysis confirmed this result and showed robust Camkk2-reporter activity in tumor-associated CD11b+ myeloid cells, but minimal activity in CD11b- non-myeloid cells (Supplementary Figure S1C, left panel). This evidence concerns the gene CAMKK2 and neoplasm.